{"id":4659,"date":"2025-03-31T18:12:15","date_gmt":"2025-03-31T18:12:15","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/rifabutin-txt\/"},"modified":"2025-03-31T18:12:15","modified_gmt":"2025-03-31T18:12:15","slug":"rifabutin-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/rifabutin-txt\/","title":{"rendered":"rifabutin.txt"},"content":{"rendered":"

CLINICAL USE <\/H3>
\nAntibacterial agent:Tuberculosis Mycobacterial infection

DOSE IN NORMAL RENAL FUNCTION <\/H3>Prophylaxis of Mycobacterium avium in patients with low CD4 count: 300 mg dailyTreatment of non-tuberculous mycobacterial disease, in combination with other drugs: 450\u2013600 mg dailyTreatment of pulmonary tuberculosis, in combination with other drugs: 150\u2013450 mg daily

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :847<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :70<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 5<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :8\u20139<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :35\u201340\/Unchanged

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>30\u201350 Dose as in normal renal function 10\u201330 Maximum 300 mg daily
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Maximum 300 mg daily

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unlikely to be dialysed. Dose as in GFR <10 mL\/min<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in GFR <10 mL\/min
  • HDF\/high flux &nbsp :Not dialysed. Dose as in GFR <10 mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in GFR=10\u201330 mL\/min

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Anti-arrhythmics: metabolism of disopyramide accelerated\n
  • Antibacterials: clarithromycin and other macrolides increase concentration of rifabutin, resulting in increased risk of uveitis \u2013 reduce rifabutin dose; reduced concentration of dapsone and clarithromycin\n
  • Anticoagulants: reduced anticoagulant effect of coumarinsAntidiabetics: reduced antidiabetic effect of chlorpropamide and tolbutamide; possibly reduced antidiabetic effect with sulphonylureas\n
  • Anti-epileptics: reduced concentration of phenytoin and carbamazepine\n
  • Antifungals: fluconazole, triazoles, posaconazole and voriconazole increase the concentration of rifabutin resulting in increased risk of uveitis \u2013 reduce rifabutin dose; rifabutin reduces concentration of posaconazole, voriconazole and itraconazole \u2013 increase voriconazole dose, avoid with itraconazole\n
  • Antipsychotics: possibly reduced aripiprazole concentration \u2013 increase dose of aripiprazole\n
  • Antivirals: amprenavir, atazanavir darunavir, nelfinavir and tipranavir and possibly nevirapine increase concentration of rifabutin \u2013 halve or reduce dose of rifabutin; efavirenz reduces the concentration of rifabutin \u2013 increase dose of rifabutin; indinavir increases rifabutin concentration\u2013 reduce dose of rifabutin; concentration of indinavir reduced when given together \u2013 increase indinavir dose; ritonavir increases the concentration of rifabutin resulting in increased risk of uveitis \u2013 avoid concomitant use; concentration of saquinavir reduced \u2013 avoid concomitant use unless another protease inhibitor is also givenAtovaquone: concentration of atovaquone reduced (possible therapeutic failure of atovaquone)\n
  • Ciclosporin: possibly reduced ciclosporin levelsCorticosteroids: reduced level of corticosteroids \u2013 double steroid dose. Give as twice daily dosageOestrogens and progestogens: reduced contraceptive effect due to increased metabolismSirolimus: reduced sirolimus concentration \u2013 avoid\n
  • Tacrolimus: possibly reduced tacrolimus trough concentration

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>Oral

    Rate of Administration <\/H4>\u2013

    Comments<\/H4>\u2013

    OTHER INFORMATION <\/H4>Can cause an orange-tan skin pigmentation as well as discoloured urineCan cause abnormal LFTs and hepatitis Can cause uveitis especially in combination with clarithromycin and fluconazoleRifabutin is a less potent CYP4503A enzyme inducer than rifampicin but similar interactions may occur.
    \n","protected":false},"excerpt":{"rendered":"

    CLINICAL USE Antibacterial agent:Tuberculosis Mycobacterial infection DOSE IN NORMAL RENAL<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4659","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4659","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4659"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4659\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4659"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4659"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4659"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}